Dealmaker’s Intentions: 2020 Market Outlook

12:30 PM - 1:45 PM, Tuesday, June 9, 2020 ・ Room 6A
With the close out of 2019 at record levels and 2020 in full swing, the biotechnology sector has proven itself to be a rewarding place for investors to devote their capital. The nature of the industry has also continually driven investors’ focus toward the long-term potential, rather than short-term gains. While 2018 witnessed biotechnology companies going public at a frantic pace, 2019 brought more hesitation due to the pre- and post-IPO price volatility and the availability of robust private capital earlier in the company lifecycle. This access to capital has allowed companies to maintain focus on the R&D product pipeline and build mature enterprises with established clinical results prior to accessing the public markets. With a strong market economy and healthy portfolio of large, private companies, it begs the question of whether the overall market will experience a cooling off period in 2020 or if we are at the beginning of a long-term growth cycle? This session will examine the path forward while highlighting the availability of quality targets in the market. A highly distinguished panel of deal-makers and investors will explore the impact these market forces will have on pharmaceutical and biotech companies as they strive to make the next big deal.

Session attendees will hear updated findings from two unique, forward-looking measures of deal-making in the industry the Syneos Health Dealmakers' Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives and business development professionals, Dealmakers' Intentions provides insight into what will likely drive the industry's partnering and M&A efforts moving forward and the implications for deal-making over the next year or more. Now in its 12th year, analysis will include year-over-year trends, deal metrics and broader M&A data.

Sponsored by Syneos Health
Moderator
photo
Managing Director, Portfolio & Commercial Strategy
Syneos Health Consulting